SGEN Share Price

Open 67.25 Change Price %
High 68.72 1 Day 1.33 1.99
Low 66.61 1 Week 2.92 4.47
Close 68.26 1 Month 3.79 5.88
Volume 447178 1 Year 30.97 83.05
52 Week High 75.36
52 Week Low 32.40
SGEN Important Levels
Resistance 2 70.22
Resistance 1 69.41
Pivot 67.86
Support 1 67.11
Support 2 66.30
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
SIRI 5.02 -1.76%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
INTC 37.43 1.35%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
IFON 0.63 34.04%
WRES 0.09 28.57%
SMSI 1.13 28.41%
EXAS 30.14 26.64%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPHC 2.80 21.21%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
PGRX 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SNCR 13.29 -46.02%
DVOX 0.05 -44.44%
More..

Seattle Genetics, Inc. (NASDAQ: SGEN)

SGEN Technical Analysis 5
As on 27th Apr 2017 SGEN Share Price closed @ 68.26 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 55.39 & Strong Buy for SHORT-TERM with Stoploss of 65.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
SGEN Target for April
1st Target up-side 68.15
2nd Target up-side 71.86
3rd Target up-side 75.57
1st Target down-side 57.57
2nd Target down-side 53.86
3rd Target down-side 50.15
SGEN Other Details
Segment EQ
Market Capital 2955180288.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.seattlegenetics.com
SGEN Address
SGEN
21823 30th Drive SE
Bothell, WA 98021
United States
Phone: 425-527-4000
Fax: 425-527-4001
SGEN Latest News
Interactive Technical Analysis Chart Seattle Genetics, Inc. ( SGEN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Seattle Genetics, Inc.
SGEN Business Profile
Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.